5705results about "Energy modified materials" patented technology

A method and apparatus for producing hair growth stimulation using light energy, topical compositions, and combinations thereof. By using photomodulation resulting from cellular responses to exposure to specific wavelengths of light, optionally in conjunction with topical compositions and procedures for enhancing the penetration of such compositions, hair follicles are activated to produce hair growth.

A method is disclosed for enhanced vaccination and genetic vaccination of mammals. The vaccination is accomplished by delivering molecules such as proteins and nucleic acids into skeletal muscle and other cells residing in the skeletal muscle in vivo. The protein or nucleic acid is first injected into the muscle at one or multiple sites. Immediately or shortly after injection, electrodes are placed flanking the injection site and a specific amount of electrical current is passed through the muscle. The electrical current makes the muscle permeable, thus allowing the pharmaceutical drug or nucleic acid to enter the cell. The efficiency of transfer permits robust immune responses using DNA vaccines and produces sufficient secreted proteins for systemic biological activity to be observed.

Photocosmetic device for use in medical or non-medical environments (e.g., a home, barbershop, or spa), which can be used for a variety of tissue treatments. Radiation is delivered to the tissue via optical systems designed to pattern the radiation and project the radiation to a particular depth. The device has a variety of cooling systems including phase change cooling solids and liquids to cool treated skin and the radiation sources. Contact sensors and motion sensor may be used to enhance treatment. The device may be modular to facilitate manufacture and replacement of parts.

Products, compositions, systems, and methods for modifying a target structure which mediates or is associated with a biological activity, including treatment of conditions, disorders, or diseases mediated by or associated with a target structure, such as a virus, cell, subcellular structure or extracellular structure. The methods may be performed in situ in a non-invasive manner by application of an initiation energy to a subject thus producing an effect on or change to the target structure directly or via a modulation agent. The methods may further be performed by application of an initiation energy to a subject in situ to activate a pharmaceutical agent directly or via an energy modulation agent, optionally in the presence of one or more plasmonics active agents, thus producing an effect on or change to the target structure. Kits containing products or compositions formulated or configured and systems for use in practicing these methods.

Products, compositions, systems, and methods for modifying a target structure which mediates or is associated with a biological activity, including treatment of conditions, disorders, or diseases mediated by or associated with a target structure, such as a virus, cell, subcellular structure or extracellular structure. The methods may be performed in situ in a non-invasive manner by placing a nanoparticle having a metallic shell on at least a fraction of a surface in a vicinity of a target structure in a subject and applying an initiation energy to a subject thus producing an effect on or change to the target structure directly or via a modulation agent. The nanoparticle is configured, upon exposure to a first wavelength λ1, to generate a second wavelength λ2 of radiation having a higher energy than the first wavelength λ1. The methods may further be performed by application of an initiation energy to a subject in situ to activate a pharmaceutical agent directly or via an energy modulation agent, optionally in the presence of one or more plasmonics active agents, thus producing an effect on or change to the target structure. Kits containing products or compositions formulated or configured and systems for use in practicing these methods.

The present invention relates to devices for detection and therapy of active atheromatous plaque and / or thin-capped fibro-atheroma ("vulnerable plaque"), using selectively targeted fluorescent, radiolabeled, or fluorescent and radiolabeled compositions. The present invention further relates to methods and devices for detection and theraphy of active atheromatous plaques and / or vulnerable plaques, using selectively targeted beta-emitting compositions, optionally comprising fluorescent compositions.

A method and apparatus are provided for treating biological cellular material with a treating agent using pulsed electrical fields provided by a waveform generator (12). The treatment method includes obtaining an electrode assembly which includes three or more parallel rows of individual electrodes (19). The electrode assembly is applied to a treatment area. Electrically conductive pathways are established between the electrodes (19) and the waveform generator (12) through an array switch (14). Successive electric fields are applied to the treatment area in the form of successive electric field waveforms from the waveform generator (12), through the array switch (14), to adjacent rows of electrodes (19), wherein each successive electric field has the same direction, and wherein polarities of rows of electrodes are reversed successively during the applying of the successive electric fields between adjacent successive rows of electrodes to the treatment area. As a result, the biological cellular material in the treatment area is treated with the treating agent unidirectionally with uniform electric fields with a minimization of the formation of deleterious electrochemistry products at the electrodes.

The present invention concerns a method and a kit, for the treatment of a selected area of the skin and / or subcutaneous tissue, and in particular for the cosmetic treatment of skin conditions such as regional fat deposits including cellulite. The method comprises heating the selected area to a sustained skin temperature of about 32 to about 50° C. for a desired period of time, using a device comprising either a heat source capable of conductively heating the selected area or, alternatively, an infra-red source for emitting infra-red with a wavelength from about 700 nm to about 15000 nm. The method also comprises administering, simultaneously or sequentially in either order, a composition containing an active agent selected from the group comprising a skin active, a nutrient absorption suppressant or a thermogenic agent, preferably a metabolic stimulating agent, more preferably a lipolytic agent, or a mixture thereof, the composition being either a topical composition for application to the selected area, or an area adjacent thereto, or an oral composition.

The present invention relates to novel therapeutic and diagnostic arrays. More particularly, the present invention is directed to dendrimer based multifunctional compositions and systems for use in disease diagnosis and therapy (e.g., cancer diagnosis and therapy). The compositions and systems generally comprise two or more separate components for targeting, imaging, sensing, and / or triggering release of a therapeutic or diagnostic material and monitoring the response to therapy of a cell or tissue (e.g., a tumor).

A method and a system for producing a change in a medium disposed in an artificial container. The method places in a vicinity of the medium at least one of a plasmonics agent and an energy modulation agent. The method applies an initiation energy through the artificial container to the medium. The initiation energy interacts with the plasmonics agent or the energy modulation agent to directly or indirectly produce the change in the medium. The system includes an initiation energy source configured to apply an initiation energy to the medium to activate the plasmonics agent or the energy modulation agent.

Materials and methods for making small magnetic particles, e.g. clusters of metal atoms, which can be employed as a substrate for immobilising a plurality of ligands. Also disclosed are uses of these magnetic nanoparticles as therapeutic and diagnostic reagents, and in the study of ligand-mediated interactions.

The present invention relates to incorporating metal nanoshells specifically designed to interact with triplet excitons in polymers. By interacting with triplet excitons, the rate of photo-oxidation can be slowed and the density of luminescence-quenching traps can be reduced.

Metallotetrapyrrolic compounds having photherapeutic properties useful in photodetection and phototherapy of target issues, particularly porphyrins and azaporphyrins that including gallium in the central pyrrolic core. Also disclosed are methods of using metallotetrapyrrolic compounds for the treatment or detection of cardiovascular disease.

Methods for preparing monomeric cytotoxic drug / carrier conjugates with a drug loading significantly higher than in previously reported procedures and with decreased aggregation and low conjugate fraction (LCF) are described. Cytotoxic drug derivative / antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described. Monomeric calicheamicin derivative / anti-CD22 antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described.

Various compositions, methods, and devices are provided that use fluorescent nanoparticles, which can function as markers, indicators, and light sources. The fluorescent nanoparticles can be formed from a fluorophore core surrounded by a biocompatible shell, such as a silica shell. In one embodiment, the fluorescent nanoparticles can be delivered to tissue to mark the tissue, enable identification and location of the tissue, and / or illuminate an area surrounding the tissue. In another embodiment, the fluorescent nanoparticles can be used on a device or implant to locate the device or implant in the body, indicate an orientation of the device or implant, and / or illuminate an area surrounding the device or implant. The fluorescent nanoparticles can also be used to provide a therapeutic effect.

Provided are electrokinetically-altered fluids (gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for use in treating diabetes and diabetes-associated conditions or disorders (e.g., insulin resistance), or symptoms thereof. Provided are electrokinetically-altered ioinic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with said inflammatory responses by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-altered fluids (e.g., electrokinetically-altered gas-enriched fluids and solutions) and therapeutic compositions.

A method for the treatment of obesity or other disorders by electrical activation or inhibition of nerves is disclosed. This activation or inhibition can be accomplished by stimulating a nerve using an electrode. The method further comprises performing a surgical procedure and / or administering a weight loss drug.

The invention relates to thermosensitive polymers which contain magnetic and / or metallic colloids and whose physical structure can be altered through magnetic induction or through the supply of energy. The invention also relates to processes for the production of such thermosensitive polymers, and the use of such polymers for diagnostic and therapeutic purposes.

Methods, devices, and compositions are described that provide for amplification of nucleic acid sequences without reliance upon temperature cycling, thus freeing the methods from conventional benchtop thermal cycling devices. Denaturation of double stranded nucleic acids, primer annealing, and precision control over primer extension by polymerase can be accomplished by applying stress to a nucleic acid. These methods can provide one ore more benefits over conventional PCR methods including: precision control over the PCR process; generally improved fidelity; improved accuracy over problematic sequences such as GC-rich or tandem repeat regions; greater sequence length; increased reaction yield; reduced experimental time; greater efficiency; lower cost; greater portability; and, robustness to various environmental parameters, such as temperature, pH, and ionic strengths.

A method of treating a pathological syndrome includes administration of an activated form of ultra-low doses of antibodies to an antigen, wherein said activated form is obtained by repeated consecutive dilution combined with external impact, and the antigen is a substance or a pharmaceutical agent exerting influence upon the mechanisms of formation of this particular pathological syndrome. Pharmaceutical agent for treating a pathological syndrome contains activated form of ultra-low doses of monoclonal, polyclonal or natural antibodies to an antigen, wherein said activated form is prepared by means of repeated consecutive dilution and external treatment, predominantly based on homeopathic technology, and said antigen is a substance or a drug acting as a direct cause of the pathological syndrome or involved in regulation of mechanisms of its formation. At that, activated forms of ultra-low doses of antibodies are raised against antigens of exogenous or endogenous origin, against autologous antigens, fetal antigens; anti-idiotypic antibodies are used too.

Disclosed are therapeutic methods for the treatment of disease material involving administration of a thermotherapeutic magnetic composition, which contains single-domain magnetic particles attached to a target-specific ligand, to a patient and application of an alternating magnetic field to inductively heat the thermotherapeutic magnetic composition. Also disclosed are methods of administering the thermotherapeutic magnetic material composition. The thermotherapeutic methods may be used where the predetermined target is associated with diseases, such as cancer, diseases of the immune system, and pathogen-borne diseases, and undesirable targets, such as toxins, reactions associated with organ transplants, hormone-related diseases, and non-cancerous diseased cells or tissue.

In certain embodiments this invention provides a nanoparticle-based technology platform for multimodal in vivo imaging and therapy. The nanoparticle-based probes detects diseased cells by MRI, PET or deep tissue Near Infrared (NIR) imaging, and are capable of detecting diseased cells with greater sensitivity than is possible with existing technologies. The probes also target molecules that localize to normal or diseased cells, and initiates apoptosis of diseased cells.

A medicament based on antibodies contains an activated form of monoclonal, polyclonal, or natural antibodies to interferon in low or ultra-low doses prepared by multiple consecutive dilutions and exposure to external factors, preferably in accordance with homeopathic technology. In order to obtain antibodies, human or heterologous interferon alpha, beta, or gamma, including recombinant interferon, is used; a mixture of various, mostly centimal, homeopathic dilutions being employed. A method of treating a pathologic syndrome, whose formation is affected by interferon, consists in the use of activated forms of antibodies to interferon alpha, beta, or gamma in low or ultra-low doses obtained by multiple consecutive dilutions and exposure to external factors.

Light treatments of sebaceous gland disorders with 5-aminolevulinic acid and photodynamic therapy are disclosed. A preferred treatment includes topical application of 5-aminolevulinic acid to the skin followed by light exposures with repeated treatment at various intervals. At low doses of ALA and photodynamic therapy (PDT) in single or multiple treatments, improvement in the sebaceous gland disorder, e.g., acne, provides the discovery that diminishment in sebum secretion and the eradication of bacteria occurs. At high doses of ALA and a single high energy PDT treatment, permanent changes to the sebaceous gland and sebum secretion have been discovered.

The present invention provides a kit and a method for targeting of a diagnostic or therapeutic agent to a target site in a mammal having a pathological condition. The kit comprises, in separate containers, (a) a first conjugate comprising a targeting moiety and a Morpholino oligomer, wherein the targeting moiety selectively binds to a primary, target-specific binding site of the target site or to a substance produced by or associated with the target site; (b) optionally, a clearing agent; and (c) a second conjugate comprising a complementary Morpholino oligomer and a diagnostic agent or therapeutic agent. The method comprises administering (a), optionally (b), and (c) to a mammal.

This invention relates to the sterilization of polymeric material by irradiation for use in a body of a mammal. We have surprisingly discovered that the sterilization of polymeric materials for use in a mammal by irradiation is improved by reducing the temperature at which the irradiation is carried out. One aspect of this invention relates to a sterilized polymeric material for use in a body of a mammal wherein said polymeric material is sterilized by irradiation at a reduced temperature Another aspect of this invention relates to methods of sustained delivery of a therapeutically active agent to a mammal by using a polymeric material that has been sterilized at a reduced temperature by irradiation.

Disclosed are thermotherapeutic compositions for treating disease material, and methods of targeted therapy utilizing such compositions. These compositions comprise a) stable single domain magnetic particles; b) magnetic nanoparticles comprising aggregates of superparamagnetic grains; or c) magnetic nanoparticles comprising aggregates of stable single magnetic domain crystals and superparamagnetic grains. These compositions may also comprise a radio isotope, potential radioactive isotope, chemotherapeutic agent. These methods comprise the administration to a patient's body, body part, body fluid, or tissue of bioprobes (energy susceptive materials attached to a target-specific ligand), and the application of energy to the bioprobes so as to destroy, rupture, or inactivate the target in the patient. Energy forms, such as AMF, are utilized to provide the energy. The disclosed methods may be useful in the treatment of a variety of indications, including cancers, diseases of the immune system, central nervous system and vascular system, and pathogen-borne diseases.

Naturally occurring miRNAs that regulate human oncogenes and methods of use therof are described. Suitable nucleic acids for use in the methods and compositions described herein include, but are not limited to, pri-miRNA, pre-miRNA, mature miRNA or fragments of variants thereof that retain the biological activity of the mature miRNA and DNA encoding a pri-miRNA, pre-miRNA, mature miRNA, fragments or variants thereof, or regulatory elements of the miRNA. The compositions containing nucleic acids are administered to a patient in need of treatment or prophylaxis of at least one symptom or manifestation of cancer. In one embodiment, the compositions are administered in an effective amount to inhibit gene expression of one or more oncogenes. Methods for treatment or prevention of at least one symptom or manifestation of cancer are also described.

The invention provides materials and methods for the administration of an effectively magnetic medication or diagnostic reagent, or for the removal, sequestration, or effective conversion to a non-deleterious condition of a deleterious substance such as a toxin (e.g., biological, chemical, or radiological compound or composition) in vivo by administering a biocompatible magnetic particle to an organism in need, e.g., by delivery to the bloodstream, with the organism optionally having an internal magnetizable stent or magnetizable seed. The materials and methods are useful in the diagnosis and treatment of a variety of acute and chronic diseases, disorders and conditions afflicting man and other organisms, as well as for the removal of a variety of deleterious substances, including toxins, with the optional aid of an external magnetic generator and an optional magnetic filtration device.